Literature DB >> 15453963

Quantitative imaging of yttrium-86 PET with the ECAT EXACT HR+ in 2D mode.

Thomas Kull1, Jochen Ruckgaber, Rolf Weller, Sven Reske, Gerhard Glatting.   

Abstract

The radionuclide 86Y potentially allows for the precise assessment of tissue radioactivity biodistribution and, thus, extrapolation of a therapeutic dose of 90Y-labeled compounds. A method to obtain quantitative images from 86Y-PET measurements after a background correction and a recalibration is presented. Cylinder and body phantom measurements with 18 F and 86Y using an ECAT EXACT HR+ tomograph were performed in 2D mode. A second-order series expansion is used to correct for the background of spurious coincidences in the sinogram. A recalibration of the positron emission tomography (PET) system, depending on the ratio of true coincidences and singles, is implemented. The correction for the nonannihilation coincidences with a second-order series expansion significantly improves the accuracy of quantitation: The lesion-to-background ratio is reproduced, and the variation of the activity concentration in the homogeneous background regions of the phantoms is smaller than 5%. The apparent activities in cold inserts of various densities is reduced to less than 15% of the concentration in the active region. The recalibration of the system works with a relative error of 0.2% +/- 2.4%. In conclusion, the used approximations lead to improved uniformity and quantitative accuracy in 86Y-PET measurements with the ECAT EXACT HR+. Copyright Mary Ann Liebert, Inc.

Mesh:

Substances:

Year:  2004        PMID: 15453963     DOI: 10.1089/cbr.2004.19.482

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  10 in total

1.  Feasibility of 90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-Spheres.

Authors:  Renaud Lhommel; Larry van Elmbt; Pierre Goffette; Marc Van den Eynde; François Jamar; Stanislas Pauwels; Stephan Walrand
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-04-27       Impact factor: 9.236

2.  Assessment of the short-lived non-pure positron-emitting nuclide (120)I for PET imaging.

Authors:  H Herzog; S M Qaim; L Tellmann; S Spellerberg; D Kruecker; H H Coenen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-15       Impact factor: 9.236

3.  Planar and SPECT imaging in the era of PET and PET-CT: can it survive the test of time?

Authors:  Abass Alavi; Sandip Basu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08       Impact factor: 9.236

4.  ARRONAX, a high-energy and high-intensity cyclotron for nuclear medicine.

Authors:  Ferid Haddad; Ludovic Ferrer; Arnaud Guertin; Thomas Carlier; Nathalie Michel; Jacques Barbet; Jean-François Chatal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-09       Impact factor: 9.236

Review 5.  Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?

Authors:  Stephan Walrand; Glenn D Flux; Mark W Konijnenberg; Roelf Valkema; Eric P Krenning; Renaud Lhommel; Stanislas Pauwels; Francois Jamar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-03-11       Impact factor: 9.236

Review 6.  Quantitative imaging of 124I and 86Y with PET.

Authors:  Mark Lubberink; Hans Herzog
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

7.  Monte Carlo modeling of cascade gamma rays in (86)Y PET imaging: preliminary results.

Authors:  Xuping Zhu; Georges El Fakhri
Journal:  Phys Med Biol       Date:  2009-06-12       Impact factor: 3.609

Review 8.  Physics of pure and non-pure positron emitters for PET: a review and a discussion.

Authors:  Maurizio Conti; Lars Eriksson
Journal:  EJNMMI Phys       Date:  2016-05-23

9.  The Beginning and Development of the Theranostic Approach in Nuclear Medicine, as Exemplified by the Radionuclide Pair 86Y and 90Y.

Authors:  Frank Rösch; Hans Herzog; Syed M Qaim
Journal:  Pharmaceuticals (Basel)       Date:  2017-06-20

Review 10.  Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs.

Authors:  Cassandra Miller; Julie Rousseau; Caterina F Ramogida; Anna Celler; Arman Rahmim; Carlos F Uribe
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.